Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Project cooperationUpdated on 12 March 2026

Bringing Cell Analysis to an Upper Dimension for Bioproduction & CGT

Andrei Constantinescu

Founder and CEO - HemaVision at HemaVision

Dijon, France

About

HemaVision is industrializing 3D cellular quality control for the life‑science industries. We bring cell analysis to an upper dimension by adding a new analytical layer above current tools: proprietary non‑destructive membrane staining, advanced multi‑plane optical imaging and AI‑based 3D reconstruction turn living cells into quantitative “holograms”, from which we extract phenotypes and QC indicators on their functional state.

This upper‑dimension layer delivers a novel cellular quality‑control module based on 3D membrane morphology and AI that complements existing bioprocess and cell analysis platforms. It fills the gap between environmental/biochemical measurements and the true condition of the producing cells, enabling earlier anomaly detection, fewer batch rejections and better process robustness across bioproduction, R&D and cell & gene therapy workflows.

For Eureka, we seek partners to build a collaborative project around:
Industrial and clinical use‑cases in bioproduction, precision fermentation, cell & gene therapy and advanced blood/transfusion products, where early detection of 3D cellular drifts in this upper analytical dimension can reduce lot failures and variability.
Technology integration of HemaVision as a software and/or hardware module into existing imaging platforms and PAT/LIMS/MES environments (e.g. live‑cell imaging, bioreactors, bioanalytics), so that partners can add a “cell functional PAT” block in a higher analytical dimension on top of their current sensors and assays.
Joint pilots and beta‑sites with imaging platforms and industrial partners to generate large, high‑value 3D datasets, validate SOPs and demonstrate impact on batch robustness, QC precision and sustainability (fewer rejected lots, less waste, better use of infrastructure).

We are particularly interested in equipment manufacturers, CDMOs, biotech/medtech companies and hospital or academic imaging platforms willing to co‑develop applications, integration APIs and future OEM modules around this new upper‑dimension cell quality layer.

Stage

  • Early
  • Execution
  • Planning

Topic

  • Biotech, Pharma and Cosmetics
  • Food, Beverages and Agriculture
  • Healthcare

Type

  • EU projects
  • Partner looking for consortium
  • Research
  • Technical
  • Coordinator looking for partners

Organisation

HemaVision

SME

Dijon, France

Similar opportunities